These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 35774245)

  • 1. Development of a T cell-redirecting bispecific antibody targeting B-cell maturation antigen for the suppression of multiple myeloma cell growth.
    Huo J; Huang Y; Zheng Z; Tay XN; Mahfut FB; Zhang W; Lam KP; Yang Y; Xu S
    Antib Ther; 2022 Apr; 5(2):138-149. PubMed ID: 35774245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells.
    DiLillo DJ; Olson K; Mohrs K; Meagher TC; Bray K; Sineshchekova O; Startz T; Kuhnert J; Retter MW; Godin S; Sharma P; Delfino F; Lin J; Smith E; Thurston G; Kirshner JR
    Blood Adv; 2021 Mar; 5(5):1291-1304. PubMed ID: 33651100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel CD3/BCMA Bispecific T-cell Redirecting Antibody for the Treatment of Multiple Myeloma.
    Xiong M; Liu R; Lei X; Fan D; Lin F; Hao W; Yuan X; Yang Y; Zhang X; Ye Z; Lu Y; Zhang Y; Wang J; Xiong D
    J Immunother; 2022 Feb-Mar 01; 45(2):78-88. PubMed ID: 34711791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma.
    Golubovskaya V; Zhou H; Li F; Berahovich R; Sun J; Valentine M; Xu S; Harto H; Sienkiewicz J; Huang Y; Wu L
    Biomedicines; 2021 Oct; 9(10):. PubMed ID: 34680541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bispecific BCMA-CD3 Antibodies Block Multiple Myeloma Tumor Growth.
    Wu L; Huang Y; Sienkiewicz J; Sun J; Guiang L; Li F; Yang L; Golubovskaya V
    Cancers (Basel); 2022 May; 14(10):. PubMed ID: 35626122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The emergence of b-cell maturation antigen (BCMA) targeting immunotherapy in multiple myeloma.
    Davis JA; Shockley A; Hashmi H
    J Oncol Pharm Pract; 2022 Jun; 28(4):960-968. PubMed ID: 35006032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene therapy with B-cell maturation antigen/CD3 bispecific antibody encoding plasmid DNA for treating multiple myeloma.
    Peng F; Wang Y; Zhao J; Liu H; Liu Z; Ding K; Zhang H; Fu R
    Br J Haematol; 2023 May; 201(3):417-421. PubMed ID: 35594370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.
    Granger K; Gaffney KJ; Davis JA
    J Oncol Pharm Pract; 2023 Apr; 29(3):722-726. PubMed ID: 36775940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An anti-B cell maturation antigen bispecific antibody for multiple myeloma.
    Ramadoss NS; Schulman AD; Choi SH; Rodgers DT; Kazane SA; Kim CH; Lawson BR; Young TS
    J Am Chem Soc; 2015 Apr; 137(16):5288-91. PubMed ID: 25826669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PHE1-based IgG-like antibody platform provides a novel strategy for enhanced T-cell immunotherapy.
    Wang L; Jiang H; Yin X; Liang T; Li G; Ding C; Yang M; Zhang L; Liu J; Xu Y
    Front Immunol; 2024; 15():1415834. PubMed ID: 38933272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
    Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
    Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical Efficacy and Safety Comparison of CD3 Bispecific and ADC Modalities Targeting BCMA for the Treatment of Multiple Myeloma.
    Panowski SH; Kuo TC; Zhang Y; Chen A; Geng T; Aschenbrenner L; Kamperschroer C; Pascua E; Chen W; Delaria K; Farias S; Bateman M; Dushin RG; Chin SM; Van Blarcom TJ; Yeung YA; Lindquist KC; Chunyk AG; Kuang B; Han B; Mirsky M; Pardo I; Buetow B; Martin TG; Wolf JL; Shelton D; Rajpal A; Strop P; Chaparro-Riggers J; Sasu BJ
    Mol Cancer Ther; 2019 Nov; 18(11):2008-2020. PubMed ID: 31434693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma.
    Hammons L; Szabo A; Janardan A; Bhatlapenumarthi V; Annyapu E; Dhakal B; Al Hadidi S; Radhakrishnan SV; Narra R; Bhutani D; Thanendrarajan S; Janz S; Zangari M; Lentzsch S; Van Rhee F; Crescencio JCR; D'Souza A; Chakraborty R; Mohan M; Schinke C
    Haematologica; 2024 Mar; 109(3):906-914. PubMed ID: 37646658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Invariant NKT cells dictate antitumor immunity elicited by a bispecific antibody cotargeting CD3 and BCMA.
    Casey M; Tu C; Harrison SJ; Nakamura K
    Blood Adv; 2022 Sep; 6(17):5165-5170. PubMed ID: 35830292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a Bispecific IgG1 Antibody Targeting BCMA and PDL1.
    Cattaneo I; Choblet S; Valgardsdottir R; Roth M; Massafra A; Beeg M; Gobbi M; Duonor-Cerutti M; Golay J
    Antibodies (Basel); 2024 Feb; 13(1):. PubMed ID: 38390876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of infectious complications with BCMA-directed therapies in multiple myeloma.
    Nath K; Shekarkhand T; Nemirovsky D; Derkach A; Costa BA; Nishimura N; Farzana T; Rueda C; Chung DJ; Landau HJ; Lahoud OB; Scordo M; Shah GL; Hassoun H; Maclachlan K; Korde N; Shah UA; Tan CR; Hultcrantz M; Giralt SA; Usmani SZ; Shahid Z; Mailankody S; Lesokhin AM
    Blood Cancer J; 2024 May; 14(1):88. PubMed ID: 38821925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy.
    Meermeier EW; Welsh SJ; Sharik ME; Du MT; Garbitt VM; Riggs DL; Shi CX; Stein CK; Bergsagel M; Chau B; Wheeler ML; Bezman N; Wang F; Strop P; Bergsagel PL; Chesi M
    Blood Cancer Discov; 2021 Jul; 2(4):354-369. PubMed ID: 34258584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma.
    Verkleij CPM; Frerichs KA; Broekmans M; Absalah S; Maas-Bosman PWC; Kruyswijk S; Nijhof IS; Mutis T; Zweegman S; van de Donk NWCJ
    Oncotarget; 2020 Nov; 11(45):4076-4081. PubMed ID: 33227097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IBI379, a novel B cell maturation antigen/CD3 bispecific T-cell engager, displays high antitumor efficacy in preclinical models of multiple myeloma.
    Fei K; Ni H; Zhu M; Kuang Z; Wu M; Wu Z; Wang F; Zhou S; Jing H; Wu W; Wu D; Bai D; Chen B
    Cancer Lett; 2022 Jun; 536():215663. PubMed ID: 35381307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.